Each tablet contains:
Bezafibrate 200 mg
Properties and Mode of Action slightly decreases LDL-cholesterol level and increases HDL-cholesterol concentration in both normotriglyceridaemic and hypertriglyceridaemic patients.
EPIBEZA is a fibric acid derivative which promotes the catabolism of triglyceride-rich lipoproteins, in particular VLDL, mediated by enhanced activity of lipoprotein lipase.
EPIBEZA may interfere with the synthesis of VLDL, possibly by inhibiting hepatic acetyl coenzyme A carboxylase.
Treatment of Type II a,Type II b,Type III, Type IV, and Type V Hyperlipoproteinaemia.
Dosage and Administration
The usual dose is 200 mg three times daily taken after food.
200 mg twice daily may be an adequate dose for maintenance.
If necessary to be given to impaired renal function or hypoalbuminaemia patients, the dose must be reduced as follows:
If Creatinine clearance is 40 - 60 ml/min., give 400 mg daily.
If Creatinine clearance is 15 - 40 ml/min., give 200 mg daily or on alternate days.
If Creatinine clearance is < 15 ml/min., and dialysis patients, give 200 mg every third day.
may enhance the effects of oral anticoagulants by displacing them from their binding sites on albumin,so, the dose of the anticoagulant must be reduced.
The dosage of anti-diabetics may need adjusting during concomitant EPIBEZA therapy.
Coadministration with statins may increase the risk of myositis-like syndrome,so,CPK must be checked at regular intervals during this combination therapy.
Severe liver or kidney impairment.
Primary biliary cirrhosis.
Gallstones or gallbladder disorders.
Pregnancy and lactation.
The most common side effects are gastrointestinal upsets including nausea and gastric discomfort.
Less frequently, headache, dizziness, vertigo, fatigue, skin rash, pruritus, alopecia, impotence and anaemia.
Rarely, muscular pain or muscular weakness.
Box of 3 blisters of 10 tablets each.